The potent and selective JAK1 inhibitor filgotinib (GLPG0634, GS-6034) has been evaluated in a 24-week phase 2B study in combination with methotrexate (MTX) in active rheumatoid arthritis (RA) patients with inadequate response to MTX (DARWIN 1 study). The data gathered demonstrates a systemic anti-inflammatory activity of filgotinib in line with its clinical efficacy observed in RA patients.
For General Inquiries and Catalog Product Orders
9800 Medical Center Drive, Building D
Rockville, MD 20850 USA
Toll Free: 800-225-5600
Phone: 301-881-5600
Email: info@ablinc.com